Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (956,444)	$ (2,491,665)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	330,639	453,791
Amortization of held-to-maturity securities, net	(8,597)	13,446
Gain from the sale of investment in Alphazyme	(989,319)	0
Foreign currency exchange loss (gain), net	11,021	(10,247)
Changes in operating assets and liabilities:
Interest receivable	28,207	65,481
Accounts receivable	(413,991)	(241,002)
Prepaid expenses and other current assets	107,610	131,299
Accounts payable	(526,556)	(679,918)
Accrued expenses	250,146	(176,396)
Deferred research and development obligation	24,464	163,859
Deferred license revenue	(44,118)	(79,031)
Net cash used in operating activities	(2,186,938)	(2,850,383)
Cash flows from investing activities
Purchases of held-to-maturity investment securities	(719,767)	(5,020,850)
Proceeds from maturities of investment securities	2,213,000	4,500,000
Proceeds from the sale of investment in Alphazyme	1,274,007	0
Net cash provided by (used in) investing activities	2,767,240	(520,850)
Cash flows from financing activities
Proceeds from exercise of options	0	42,350
Net cash provided by financing activities	0	42,350
Effect of exchange rate changes on cash	(484)	(568)
Net decrease in cash and cash equivalents	579,818	(3,329,451)
Cash and cash equivalents at beginning of period	5,794,272	15,748,480
Cash and cash equivalents at end of period	6,374,090	12,419,029
Non-cash item
Vesting of restricted stock units	$ 342,186	$ 0